Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached

by Massimo Breccia
Published 2020-02-01

Nilotinib: selective inhibitor as second-line therapy

by Massimo Breccia
Published 2015-10-01

Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib

by Massimo Breccia
Published 2015-10-01

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome

by Massimo Breccia
Published 2015-10-01

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib

by Giuliana Alimena, Massimo Breccia
Published 2008-10-01

SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

by Massimo Breccia, Giuliana Alimena
Published 2014-01-01

Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia

by matteo molica, elisabetta abruzzese, massimo breccia
Published 2020-08-01

MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY

by Francesco Lococo, Roberto Latagliata, Massimo Breccia
Published 2013-06-01

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge

by Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Massimo Breccia
Published 2021-02-01

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

by Matteo Molica, Emilia Scalzulli, Gioia Colafigli, Robin Foà, Massimo Breccia
Published 2019-02-01

Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia

by Massimo Breccia, Gioia Colafigli, Luisa Quattrocchi, elisabetta abruzzese, giuliana alimena
Published 2016-02-01

Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

by Fausto Castagnetti, Fausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, Giuseppe Saglio, Massimo Breccia
Published 2021-03-01

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia

by Massimo Breccia, Elisabetta Abruzzese, Mario Annunziata, Luigia Luciano, Simona Sica, Simona Sica
Published 2021-03-01

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

by Massimo Breccia, Michele Baccarani, Gianantonio Rosti, Francesco Cottone, Laura Cannella, François Guilhot, Marco Vignetti, Fabio Efficace
Published 2017-10-01

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia

by Mario Annunziata, Massimiliano Bonifacio, Massimo Breccia, Fausto Castagnetti, Antonella Gozzini, Alessandra Iurlo, Patrizia Pregno, Fabio Stagno, Giorgina Specchia
Published 2020-06-01

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

by Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena
Published 2011-05-01

LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

by Michelina Santopietro, Giuseppina Loglisci, Roberto Latagliata, Corrado Girmenia, Massimo Breccia, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena
Published 2011-01-01

Molecular Minimal Residual Disease Monitoring In Npm1-Mutated Acute Myeloid Leukemia: A Single Institution Experience

by Laura Cesini, Clara Minotti, Saveria Capria, Silvia Maria Trisolini, Daniela Diverio, Danilo Alunni Fegatelli, Claudio Cartoni, Massimo Breccia, Roberto Latagliata, Giulia Ciotti, Germana Tartaglia, Gioia Colafigli, Ida Carmosino, Maurizio Martelli
Published 2020-09-01

How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis f...

by Massimo Breccia, Pier Paolo Olimpieri, Odoardo Olimpieri, Fabrizio Pane, Alessandra Iurlo, Paolo Foggi, Alessia Cirilli, Antonietta Colatrella, Marcello Cuomo, Lucia Gozzo, Valentina Summa, Paolo Corradini, Pierluigi Russo, the AIFA’s Monitoring Registries Group
Published 2020-06-01

EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS

by Salvatore Giacomo Morano, Lorenzo Coppola, Roberto Latagliata, Paola Berneschi, Antonio Chistolini, Alessandra Micozzi, Corrado Girmenia, Massimo Breccia, Gregorio Brunetti, Angela Matturro, Giovanni Rosa, Pietro Guerrisi, Franco Mandelli, Roberto Foà, Giuliana Alimena
Published 2014-02-01